Opus Genetics, Inc. — Form 8-K
Filed October 15, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 68/100
What the filing says
Opus Genetics presented clinical data at Retina in Rio 2026 (October 15, 2026) for two investigational gene therapies for inherited retinal diseases. OPGx-BEST1 showed improved retinal sensitivity in 3 of 4 evaluable participants (75%) in low-dose Cohort 1 of a Phase 1/2 trial; high-dose Cohort 2 has completed enrollment with 11 participants. OPGx-LCA5 demonstrated sustained visual acuity improvements through 24 months in 3 adult participants and through 6 months in 3 pediatric participants in an ongoing Phase 1/2/3 trial; Phase 3 dosing initiation is expected in Q4 2026, with both the natural history and treatment cohorts fully enrolled. No specific financial figures, partnership counterparties, or equity transactions are disclosed in this 8-K filing.
Why this rating
Early-stage biotech ($45.9M market cap) with two lead programs advancing to later-stage trials. Positive Phase 1/2 data and progression to Phase 3 for OPGx-LCA5 represent meaningful clinical de-risking and a credible path to potential regulatory approval, materially reducing execution risk—significant for a company of this size.
See more from October 15, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.